Sucampo Americas Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sucampo Americas (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $14.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$14.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$12.0M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel